Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 456 • 2017 ACR/ARHP Annual Meeting
Time from First Symptom Onset to First Advanced Therapy Amongst RA Patients in Latin America
Ivanio Pereira¹, Valderilio F Azevedo², Wilson Bautista-Molano³, Julio Casasola⁴, Generoso Guerra⁵, David Vega-Morales⁶, Enrique R Soriano⁷, Diana Rocio Gil⁸, José Antonio Maldonado-Cocco⁹, Leandro Aldunate¹⁰ and Steve Lobosco¹¹, ¹Rheumatology, Universidade Federal de Santa Catarina, Hospital Universitário, Divisão de Reumatologia.Brazil, Florianopolis, Brazil, ²Adjunct Professor of Rheumatology, Federal University of Paraná; Brazil, Curitiba, Brazil, ³School of Medicine, Universidad Militar Nueva Granada and Rheumatology Department Hospital Militar. Colombia, Bogotá, Colombia, ⁴Rheumatology, Hospital General de Mexico, Mexico, Mexico, ⁵Centro Médico Paitilla Internal Medicine and Rheumatology Department. Panama, Panama City, Panama, ⁶Universidad Autónoma de Nuevo León. Rheumatology Service, Internal Medicine Department, Hospital Universitario "Dr. José Eleuterio González". Mexico, Monterrey, Mexico, ⁷Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸ART Medica - Hospital Universitario Mayor MEDERI Internal Medicine and Rheumatology. Colombia., Bogota, Colombia, ⁹Buenos Aires University, Consulting Professor of Rheumatology, Buenos Aires University. Argentina, Buenos Aires, Argentina, ¹⁰Immunology, Janssen Latin America, Buenos Aires, Argentina, ¹¹Adelphi, Immunology Director- Adelphi Group, Manchester, United Kingdom
Background/Purpose: To understand the RA patient pathway in Latin America from first symptom onset; including time to diagnosis and to first advanced treatment. Methods: Data…
Abstract Number: 1332 • 2017 ACR/ARHP Annual Meeting
Periostin Deficiency Exacerbates Joint Inflammation and Bone Destruction in Mouse Models of Rheumatoid Arthritis
Yun-Hong Cheon, Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, Korea, Republic of (South)
Background/Purpose: Periostin (POSTN), a matricellular protein, is involved in many fundamental biological processes such as bone metabolism, cell proliferation, cell invasion, and angiogenesis. Also, POSTN…
Abstract Number: 2356 • 2017 ACR/ARHP Annual Meeting
Disease Severity Impacts the Relationships of Apelin Concentrations with Arterial Function in Patients with Rheumatoid Arthritis
Sule Gunter¹, Chanel Robinson¹, Gavin Norton¹, Angela Woodiwiss¹, Hon-Chun Hsu¹, Linda Tsang², Aletta Millen¹ and Patrick Dessein³, ¹Physiology, University of Witwatersrand, Johannesburg, South Africa, ²Rheumatology, Universitair Ziekenhuis Brussel, Brussels, Belgium, ³Rheumatology, Vrije Universiteit Brussel and Universitair Ziekenhuis Brussel, Brussels, Belgium
Background/Purpose: Patients with (RA) experience impaired inflammation induced arterial and endothelial function. Apelin can improve arterial function by enhancing the expression of endothelial nitric oxide…
Abstract Number: 2963 • 2017 ACR/ARHP Annual Meeting
Sirukumab Improves Synovial Vascularity As Measured By Power Doppler Sonography in Rheumatoid Arthritis Patients from As Early As Week 4 in a Phase 3 Trial
Bidisha Dasgupta¹, Kristen Sweet¹, Dick DeVries², Benjamin Hsu¹, Ian Gourley¹, Matthew Loza¹ and Peter C. Taylor³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Biologics Europe, Leiden, Netherlands, ³Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Ultrasound (US) is an established non-invasive tool for sensitively assessing disease activity at the individual‐joint level in rheumatoid arthritis (RA). Synovial thickness is detectable…
Abstract Number: 457 • 2017 ACR/ARHP Annual Meeting
Levels of Satisfaction with RA Treatment and Associated Alignment between Rheumatologists and Their Patients across Latin America
Enrique R Soriano¹, José Antonio Maldonado-Cocco², David Vega-Morales³, Diana Rocio Gil⁴, Ivanio Pereira⁵, Generoso Guerra⁶, Wilson Bautista-Molano⁷, Julio Casasola⁸, Valderilio F Azevedo⁹, Leandro Aldunate¹⁰ and Steve Lobosco¹¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ²Buenos Aires University, Consulting Professor of Rheumatology, Buenos Aires University. Argentina, Buenos Aires, Argentina, ³Universidad Autónoma de Nuevo León. Rheumatology Service, Internal Medicine Department, Hospital Universitario "Dr. José Eleuterio González". Mexico, Monterrey, Mexico, ⁴ART Medica - Hospital Universitario Mayor MEDERI Internal Medicine and Rheumatology. Colombia., Bogota, Colombia, ⁵Rheumatology, Universidade Federal de Santa Catarina, Hospital Universitário, Divisão de Reumatologia.Brazil, Florianopolis, Brazil, ⁶Centro Médico Paitilla Internal Medicine and Rheumatology Department. Panama, Panama City, Panama, ⁷School of Medicine, Universidad Militar Nueva Granada and Rheumatology Department Hospital Militar. Colombia, Bogotá, Colombia, ⁸Rheumatology, Hospital General de Mexico, Mexico, Mexico, ⁹Adjunct Professor of Rheumatology, Federal University of Paraná; Brazil, Curitiba, Brazil, ¹⁰Immunology, Janssen Latin America, Buenos Aires, Argentina, ¹¹Adelphi, Immunology Director- Adelphi Group, Manchester, United Kingdom
Background/Purpose: To assess levels of rheumatologist and patient satisfaction with RA treatment across Latin America and any disconnects that may exist between the two in…
Abstract Number: 1342 • 2017 ACR/ARHP Annual Meeting
Comprehensive Provider Judgment Outweighs Disease Activity Measures in the Decision to Not Escalate Therapy in Patients with Moderate to Severe Rheumatoid Arthritis
Jacob R. Stever¹, Brian Sauer², Chia-Chen Teng, MS¹, Neil Accortt³, David Collier⁴ and Grant Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Amgen, Inc., Thousand Oaks, CA
Title: Comprehensive provider judgment outweighs disease activity measures in the decision to not escalate therapy in patients with moderate to severe rheumatoid arthritis. Authors: Stever,…
Abstract Number: 2365 • 2017 ACR/ARHP Annual Meeting
Poor Cardiovascular Risk Management in Rheumatoid Arthritis Patients Despite an Explicit Cardiovascular Risk Management Program
Maaike Heslinga¹, Inge van den Oever², E. Griep³, Hanneke Griep-Wentink³, Yvo M. Smulders⁴, WF Lems⁵, Maarten Boers⁶, Alexandre Voskuyl⁷, Mike J.L. Peters⁴, Dirkjan van Schaardenburg² and Michael Nurmohamed⁸, ¹Amsterdam Rheumatology immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ³Rheumatology, Antonius Hospital, Sneek, Netherlands, ⁴Internal Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁵Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁶Epidemiology & Biostatistics, VU Univ Medical Center F-wing, Amsterdam, Netherlands, ⁷Department of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁸Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands
Background/Purpose: In 2011, we started a cardiovascular (CV) risk management program for rheumatoid arthritis (RA) patients visiting Reade in the Netherlands. We previously reported the…
Abstract Number: 2967 • 2017 ACR/ARHP Annual Meeting
Adding Ultrasound to the Treat-to-Target Strategy Shows No Benefit in Achievement of Remission: Results from the Biodam Cohort
Alexandre Sepriano¹, Sofia Ramiro², Robert B.M. Landewé³, Désirée van der Heijde¹, Sarah Ohrndorf⁴, Oliver FitzGerald⁵, Marina Backhaus⁶, Maggie Larche⁷, Joanne Homik⁸, Alain Saraux⁹, Hilde B. Hammer¹⁰, Lene Terslev¹¹, Mikkel Østergaard¹¹, Gerd R. Burmester¹², Bernard Combe¹³, Maxime Dougados¹⁴, Carol A Hitchon¹⁵, Gilles Boire¹⁶, Robert G. Lambert⁸, Rana Dadashova¹⁷, Joel Paschke¹⁸, Edna Hutchings¹⁷ and Walter P. Maksymowych¹⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁴Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁵ASRI, Dublin, Ireland, Dublin, Ireland, ⁶Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ⁷Medicine, McMaster University, Hamilton, ON, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, ¹⁰Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ¹¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ¹²Department of Rheumatology and Clinical Immunolgy, Charité University Hospital, Berlin, Germany, ¹³Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, ¹⁴Paris-Descartes University,, Paris, France, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁷CaRE Arthritis, Edmonton, AB, Canada, ¹⁸CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: While, a Treat-to-Target strategy (T2T), treating patients with rheumatoid arthritis (RA) towards a certain target (eg. clinical remission; T2T-REM), is highly recommended, several patients…
Abstract Number: 474 • 2017 ACR/ARHP Annual Meeting
Comparison of Tofacitinib Efficacy in Patients with Moderate Vs Severe Rheumatoid Arthritis: Pooled Analysis of Phase 3 Studies
Sergio Schwartzman¹, Prashanth Sunkureddi², Liza Takiya³, Mark Snyder³, Haiyun Fan⁴, Tatjana Lukic⁵, Jacqui Roberts⁶ and William F C Rigby⁷, ¹Hospital for Special Surgery, New York, NY, ²Clear Lake Rheumatology, Nassau Bay, TX, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Tadworth, United Kingdom, ⁷Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We evaluated tofacitinib 5 and 10 mg twice daily (BID)…
Abstract Number: 1347 • 2017 ACR/ARHP Annual Meeting
Ultrasonography and Synovial Histology in the RA Patients in Remission
Asami Abe¹, Hajime Ishikawa² and Kunihiko Wakaki³, ¹Rheumatplogy, Niigata Rheumatic Center, Shibata, Japan, ²Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ³Pathology, Niigata Prefectural Shibata Hospital, Shibata, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), the early diagnosis and early medical treatment via tight control have become increasingly important with the advent…
Abstract Number: 2373 • 2017 ACR/ARHP Annual Meeting
Low or High BMI Negatively Impacts RA Disease Activity in an Asian RA Cohort
Claire Teo¹, KP Leong², CM Woo³, X Tang³, J WL Tan⁴, TY Lian⁴ and ET Koh², ¹Rheumatology, Allergy and Immunology Department, Tan Tock Seng Hospital, Singapore, Singapore, ²Rheumatology/Allerg/Immunology, Tan Tock Seng Hospital, Singapore, Singapore, ³Clinical Research and Innovation Office, Tan Tock Seng Hospital, Singapore, Singapore, ⁴Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: The association of body mass index (BMI) with the outcomes of rheumatoid arthritis (RA) has been inconsistent in the literature. It is postulated that…
Abstract Number: 123 • 2017 ACR/ARHP Annual Meeting
Relationship between Shift Work and the Onset of Rheumatoid Arthritis; Results from a Swedish Case-Control Study
Lars Alfredsson¹, Anna Karin Hedström², Torbjörn Åkerstedt³ and Lars Klareskog⁴, ¹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Stockholm University; Karolinska Intitutet, Stockholm, Sweden, ⁴Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Shift work has previously been associated with increased RA risk in females. The aim of this study was to investigate the potential association between…
Abstract Number: 475 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient Characteristics Also Predict Response to Therapy with Biologic Agents: Results from the Corrona Certain Study
Dimitrios A. Pappas¹, James Murray², Carol J. Etzel¹, David R Nelson², Bernice Gershenson³, Katherine C. Saunders¹, Sabrina Rebello¹ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²Eli Lilly and Company, Indianapolis, IN, ³University of Massachusetts Medical School, Worcester, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Response to biologic agents approved for RA may be associated with patient reported factors that are not related to disease and usually not included…
Abstract Number: 1403 • 2017 ACR/ARHP Annual Meeting
Mediterranean Diet Is Inversely Associated with Risk of Rheumatoid Arthritis: A Swedish Population Based Case-Control Study
Daniela Di Giuseppe¹, Kari Johansson², Johan Askling³ and Lars Alfredsson⁴, ¹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Karolinska Institutet, Solna, Sweden, ³Unit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The Mediterranean Diet has been associated with lower mortality and risk of cardiovascular diseases and cancer. Although its components have been analyzed in several…
Abstract Number: 2408 • 2017 ACR/ARHP Annual Meeting
Early Frailty Syndrome in Rhematoid Arthitis: Screening Using the Frail Scale
Elisa Trujillo^1,2 and Maria del Mar Trujillo³, ¹Rheumatology, Hospital Universitario de Canarias, La Laguna.Tenerife, Spain, ²Hospital Universitario de Canarias, Servicio de Reumatologia, Tenerife, Spain, ³Servicio de Evaluación y Planificación, Fundación Canaria de Investigación Sanitaria (FUNCANIS) Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Santa cruz de Tenerife, Spain
Background/Purpose: Frailty is defined as a syndrome of physiological decline in late life, characterized by marked vulnerability to adverse health outcomes. Frail adults are less…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].